Literature DB >> 30982622

Complications and survival rates of 55 metal-ceramic implant-supported fixed complete-arch prostheses: A cohort study with mean 5-year follow-up.

Panos Papaspyridakos1, Thaisa Barizan Bordin2, Zuhair S Natto3, Khaled El-Rafie4, Sarah E Pagni5, Konstantinos Chochlidakis6, Carlo Ercoli7, Hans-Peter Weber8.   

Abstract

STATEMENT OF PROBLEM: Long-term outcomes with metal-ceramic (MC) implant-supported fixed complete dental prostheses (IFCDPs) are scarce.
PURPOSE: The purpose of this retrospective study was to assess the rate of biologic and technical complications in a cohort of edentulous patients treated with MC IFCDPs by residents after a mean clinical follow-up of 5 years (range: 1 to 12 years).
MATERIAL AND METHODS: Forty-one participants with 55 MC IFCDPs underwent a single-visit comprehensive examination that included a medical and dental history review and clinical and radiographic examinations. All supporting implants and prostheses were examined for biologic and technical complications. Life table analysis and Kaplan-Meier survival curves were calculated.
RESULTS: Of 359 moderately rough surface dental implants, 2 had failed in 1 patient after 11 years of functional loading, yielding a cumulative implant survival rate of 99.4%. Owing to the implant failure, 1 of 55 edentulous arches restored with IFCDPs failed, yielding a cumulative prosthesis survival rate of 98.2% after mean observation period of 5.0 years. Soft tissue recession was the most frequent minor biologic complication (annual rate 7.8% at the prosthesis level) for both cement and screw-retained IFCDPs (group C and S), and peri-implantitis (annual rate 1.6% at the implant level) the most frequent major biologic complication. Wear of porcelain (annual rate 8.0% at the prosthesis level) was the most frequent minor technical complication for both groups, and fracture of porcelain (annual rate 0.8% at the dental-unit level) was the most frequent major technical complication. Minor complications were the most frequent in both the groups (cement and screw retained).
CONCLUSIONS: High implant and prosthesis survival rates (above 98%) were achieved, yet substantial complication rates were encountered. The most frequent major biologic complication was peri-implantitis, with a 5-year implant-based rate of 8% (95% confidence interval [CI]: 5.8-11.1), whereas the most frequent major complication was fracture of porcelain with a 5-year dental unit-based rate of 4%. The estimated cumulative rates for "prosthesis free of biologic complications" were 50.4% (95% CI: 36.4% to 63.0%) at 5 years and 10.1% (95% CI: 3.5% to 20.8%) at 10 years, whereas for "prosthesis free of technical complications," they were 56.4% (95% CI: 41.7% to 68.8%) at 5 years and 9.8% (95% CI: 3.2% to 21.0%) at 10 years.
Copyright © 2019 Editorial Council for the Journal of Prosthetic Dentistry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30982622     DOI: 10.1016/j.prosdent.2019.01.022

Source DB:  PubMed          Journal:  J Prosthet Dent        ISSN: 0022-3913            Impact factor:   3.426


  3 in total

1.  What is the prevalence of peri-implantitis? A systematic review and meta-analysis.

Authors:  Pedro Diaz; Esther Gonzalo; Luis J Gil Villagra; Barbara Miegimolle; Maria J Suarez
Journal:  BMC Oral Health       Date:  2022-10-19       Impact factor: 3.747

2.  Survival and success rates of soft-milled cobalt-chromium-ceramic full-arch screw-retained implant-supported prostheses: a 2- to 7-year follow-up retrospective study.

Authors:  S Levartovsky; A Arieli; N Fridenberg; S Matalon; R Pilo
Journal:  Clin Oral Investig       Date:  2021-02-22       Impact factor: 3.573

3.  A 4 Year Human, Randomized, Radiographic Study of Scalloped versus Non-Scalloped Cemented Implants.

Authors:  Bruna Sinjari; Gianmaria D'Addazio; Manlio Santilli; Barbara D'Avanzo; Imena Rexhepi; Antonio Scarano; Tonino Traini; Maurizio Piattelli; Sergio Caputi
Journal:  Materials (Basel)       Date:  2020-05-10       Impact factor: 3.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.